Skip to main content

Table 1 Demographic, and clinical features of 199 consecutive CHD patients from Northern Italy with available evaluation of C282Y and H63D HFE genotype (183 with A736V TMPRSS6 evaluation) and 188 healthy controls

From: The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis

 

All patients

Ferritin >30 ng/ml and CRP <1 mg/dl

Controls

N=

199

86

188

Gender F

79 (40)

40 (47)

82 (44)

Age years

64.3±14 c

63.8±14

60.0±17

BMI Kg/m2

22.5±5 c

21.9±4 c

26.2±4.2

Dialysis duration months

34 {13-82}

37 {16-87}

-

Kt/V

1.3±0.2

1.3±0.2

-

Creatinine mg/dl

9.9±2.5 c

10.0±3 c

0.8±0.2

Active smoke

47 (24)

17 (20)

23 (16)

Albumin g/100 ml

3.7±0.5

3.8±0.4

-

CRP mg/dl

0.83 {0.4-2.5} c

0.40 {0.3-0.6} c

0.1 {0-0.2}

Hb g/dl

10.8±1.2 c

10.9±1.1 c

14.7±1.1

MCV fl

96±8 c

96±8 c

92±4

Serum iron μg/dl

55±23 c

58±19 c

98±25

Transferrin mg/dl

190±37 c

182±32 c

240±34

TS%

24.7±10 c

26.5±10 c

29.0±7

Ferritin ng/ml

265 {155-411} c

280 {204-445} c

84 {55-128}

Epo IU/Kg/week

100 {59-180}

106 {69-179}

0

Fe i.v. mg/month

94 {0-185}

93 {0-142}

0

Hepcidin-20 a nM

0.55 {0.55-5.3} c

1.39 {0.55-5.8}

0.87 {0.55-3.35}

Hepcidin-20 detectable

44 (45)

23 (51)

104 (55)

Hepcidin-25 b nM

7.1 {0.55-17.1}

6.8 {0.55-17.6}

7.4 {4.5-11.9}

Hepcidin-25 / ferritin b

0.024 c

0.021 c

0.080

 

{0.007-0.067}

{0.005-0.051}

{0.046-0.14}

  1. ():% values, {}: interquartile range, CRP: C reactive protein, Hb: hemoglobin, MCV: mean corpuscular volume, TS: transferrin saturation, Epo: erythropoietin, IU: international units, i.v.: intravenous, wt: wild-type, available in 99 CHD patients (45 with ferritin >30 ng/ml and CRP <1 mg/dl) b available in 157 CHD patients (57 with ferritin >30 ng/ml and CRP <1 mg/dl); c p < 0.05 vs. healthy controls.